1. Home
  2. NKTX vs PFO Comparison

NKTX vs PFO Comparison

Compare NKTX & PFO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • NKTX
  • PFO
  • Stock Information
  • Founded
  • NKTX 2015
  • PFO 1991
  • Country
  • NKTX United States
  • PFO United States
  • Employees
  • NKTX N/A
  • PFO N/A
  • Industry
  • NKTX Biotechnology: Pharmaceutical Preparations
  • PFO Finance Companies
  • Sector
  • NKTX Health Care
  • PFO Finance
  • Exchange
  • NKTX Nasdaq
  • PFO Nasdaq
  • Market Cap
  • NKTX 123.5M
  • PFO 121.4M
  • IPO Year
  • NKTX 2020
  • PFO N/A
  • Fundamental
  • Price
  • NKTX $1.97
  • PFO $9.60
  • Analyst Decision
  • NKTX Strong Buy
  • PFO
  • Analyst Count
  • NKTX 5
  • PFO 0
  • Target Price
  • NKTX $13.50
  • PFO N/A
  • AVG Volume (30 Days)
  • NKTX 539.6K
  • PFO 31.8K
  • Earning Date
  • NKTX 11-06-2025
  • PFO 01-01-0001
  • Dividend Yield
  • NKTX N/A
  • PFO 6.51%
  • EPS Growth
  • NKTX N/A
  • PFO N/A
  • EPS
  • NKTX N/A
  • PFO N/A
  • Revenue
  • NKTX N/A
  • PFO N/A
  • Revenue This Year
  • NKTX N/A
  • PFO N/A
  • Revenue Next Year
  • NKTX N/A
  • PFO N/A
  • P/E Ratio
  • NKTX N/A
  • PFO N/A
  • Revenue Growth
  • NKTX N/A
  • PFO N/A
  • 52 Week Low
  • NKTX $1.31
  • PFO $6.90
  • 52 Week High
  • NKTX $6.49
  • PFO $8.51
  • Technical
  • Relative Strength Index (RSI)
  • NKTX 41.11
  • PFO 82.32
  • Support Level
  • NKTX $2.00
  • PFO $9.40
  • Resistance Level
  • NKTX $2.08
  • PFO $9.31
  • Average True Range (ATR)
  • NKTX 0.11
  • PFO 0.05
  • MACD
  • NKTX -0.03
  • PFO 0.03
  • Stochastic Oscillator
  • NKTX 2.35
  • PFO 100.00

About NKTX Nkarta Inc.

Nkarta Inc is a clinical-stage biopharmaceutical company pioneering the development of allogeneic, off-the-shelf engineered natural killer (NK) cell therapies. The Company is engaged in leveraging the natural potent power of NK cells to identify and kill abnormal cells and recruit adaptive immune effectors to generate responses that are specific and durable. The company is combining its NK expansion platform technology with proprietary cell engineering technologies to generate an abundant supply of NK cells, engineer enhanced NK cell recognition of therapeutic targets, and improve persistence for sustained activity in the body for the treatment of cancer.

About PFO Flaherty & Crumrine Preferred and Income Opportunity Fund Incorporated

Flaherty & Crumrine Prfd Income Oppo is the United States-based diversified, closed-end management investment company. Its primary investment objective is to provide its common shareholders with high current income consistent with the preservation of capital. The fund invests in a diversified portfolio of preferred securities which includes traditional preferred stocks eligible for the inter-corporate dividends received a deduction and fully taxable preferred securities.

Share on Social Networks: